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Abstract
Background: Vagus nerve activation impacts inflammation. Therefore, we hypothesized that vagal nerve
stimulation (VNS) influenced arterial wall inflammation as measured by 18F-FDG uptake.
Results: Ten patients with left-sided VNS for refractory epilepsy were studied during stimulation (VNS-on) and in
the hours after stimulation was switched off (VNS-off). In nine patients, 18F-FDG uptake was measured in the right
carotid artery, aorta, bone marrow, spleen, and adipose tissue. Target-to-background ratios (TBRs) were calculated to
normalize the respective standardized uptake values (SUVs) for venous blood pool activity. Median values are
shown with interquartile range and compared using the Wilcoxon signed-rank test. Arterial SUVs tended to be
higher during VNS-off than VNS-on [SUVmax all vessels 1.8 (1.5–2.2) vs. 1.7 (1.2–2.0), p = 0.051]. However, a larger
difference was found for the venous blood pool at this time point, reaching statistical significance in the vena cava
superior [meanSUVmean 1.3 (1.1–1.4) vs. 1.0 (0.8–1.1); p = 0.011], resulting in non-significant lower arterial TBRs during
VNS-off than VNS-on. Differences in the remaining tissues were not significant. Insulin levels increased after VNS was
switched off [55.0 pmol/L (45.9–96.8) vs. 48.1 pmol/L (36.9–61.8); p = 0.047]. The concurrent increase in glucose
levels was not statistically significant [4.8 mmol/L (4.7–5.3) vs. 4.6 mmol/L (4.5–5.2); p = 0.075].
Conclusions: Short-term discontinuation of VNS did not show a consistent change in arterial wall 18F-FDG-uptake.
However, VNS did alter insulin and 18F-FDG blood levels, possibly as a result of sympathetic activation.
Keywords: Vagal nerve stimulation (VNS), Inflammation, Atherosclerosis, Positron emission tomography (PET),
Metabolism
Background
The vagus nerve (VN) is the longest cranial nerve
and stretches from the medulla to the visceral organs.
The nerve is comprised of multiple different nerve
fibers, from afferent fibers from visceral organs (60–
80% of VN fibers) to cholinergic parasympathetic pre-
ganglionic efferent fibers using acetylcholine (ACh) as
neurotransmitter [1]. Additionally, sympathetic nerve
fibers join the vagus nerve from the cervical level
downwards [2]. From as early as the end of the nine-
teenth century, effects of vagal nerve stimulation
(VNS) have been studied in multiple conditions [3, 4].
Currently, VNS is approved as a therapeutic option in
refractory epilepsy, reducing seizure frequency and se-
verity, and refractory depression [3, 4]. The exact
mechanism of VNS in these diseases is still unknown,
but its effects are probably the result of central neu-
romodulatory mechanisms [4].
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Current studies focus on new applications of VNS in a
broad range of diseases including inflammatory condi-
tions [4]. This indication is based on the effect of both
the afferent and efferent VN as part of the so-called in-
flammatory reflex [5]. The afferent VN confers signals to
the brain from inflammatory processes and activates the
sympathetic nervous system and hypothalamic–pituit-
ary–adrenal (HPA) axis, which consecutively inhibit
chronic inflammation [6, 7]. The efferent VN is part of
the cholinergic anti-inflammatory pathway (CAP) [8].
This is a complex feedback mechanism responsible for a
central inhibition of peripheral inflammatory responses
[9]. The exact mechanism of the CAP remains to be elu-
cidated, but animal research has revealed the following:
(1) stimulation of central, but not peripheral muscarinic
acetylcholine receptors (mAChRs) results in an anti-
inflammatory reaction [10]; (2) peripheral stimulation of
α7-nicotinic acetylcholine receptors (nAChRs) expressed
by macrophages inhibits TNF-α production [11]; (3)
splenectomy disables the anti-inflammatory effect of
VNS [12]; (4) surgical sympathetic denervation of the
spleen and/or noradrenaline depletion prevents CAP
function [13]; and (5) ACh-producing T cells are neces-
sary for a functioning CAP [14]. These mechanisms may
also be involved in the inflammatory cascade of the ath-
erosclerotic disease process [15].
In this exploratory subgroup analysis, we aimed to
study the anti-inflammatory effect of VNS on the arterial
wall by comparing arterial wall fluorodeoxyglucose (18F-
FDG) uptake on positron emission tomography com-
puted tomography (PET/CT) during VNS and during a
period in which VNS was switched off within the same
patient. We expected VNS to reduce arterial inflamma-
tion and thus 18F-FDG uptake, since arterial wall 18F-
FDG uptake as visualized and measured with PET/CT, is
an established marker for inflammation in atheroscler-
osis [16]. However, 18F-FDG is a glucose analogue, and
thus behaves as glucose and is affected by VNS’ interfer-
ence with glucose metabolism.
Methods
Study protocol approval and study aim
This is a subgroup analysis of a prospective trial, which
included a total of 15 patients and studied the effects of
VNS on the activation of brown adipose tissue with 18F-
FDG PET/CT. The initial study was approved by the
local medical ethics committee of the academic hospital
and the University of Maastricht (AZM/UM) and regis-
tered in the clinical trial register at ClinicalTrials.gov
under NCT01491282 [17]. All participants gave written
informed consent before the onset of the study. Partici-
pants were selected from patients with refractory epi-
lepsy treated with VNS who visited the outpatient clinic
of our tertiary expertise center for epilepsy. Details on
in- and exclusion criteria and VNS principles can be
found in Table 1 and in the original study by Vijgen
et al. [17]. This subgroup analysis aimed to include the
ten participants from the initial study population, who
underwent 18F-FDG PET/CT once with active (VNS-on)
and once with deactivated VNS (VNS-off) to study the
effect of VNS on arterial wall inflammation. For this
additional analysis, the local medical ethics committee
waived additional informed consent.
Subject characteristics
The ten patients were six females and four males with a
median age of 45 years (interquartile range (IQR) 33–
52). Stimulation parameters can be found in Table 2.
Characteristics for all subjects (n = 10) can be found in
Table 3. At the time of the first (VNS-on) scan, the me-
dian time period since VNS implantation had been 56
months (IQR 46–66).
Study design
Ten participants underwent 18F-FDG PET/CT under
thermoneutral and fasted conditions twice; once with ac-
tive VNS, and once after deactivation of VNS. The me-
dian time period between the two scans was 14 (IQR
14–49) days. Because the VNS-off scan of one partici-
pant could not be adequately reconstructed, this patient
was excluded from the PET-data analysis, resulting in
the nine participants included in this analysis. However,
all other data from this patient were complete and thus
used for analyses of the non-PET-related data.
During deactivation, VNS was turned off in the morn-
ing at 9.30 am and turned back on at the end of the test
day around 2 pm. All PET/CTs were performed at 1 pm,
3.5 h after VNS was switched off. On the same day, par-
ticipants also underwent additional tests to study, among
other things, energy expenditure. This was done by
Table 1 In- and exclusion criteria
Inclusion Exclusion
• 18-65 years of age • Daily seizures
• VNS for refractory epilepsy • Pregnancy
• Stable VNS and epilepsy medication > 1 month • Ketogenic diet
• Mental retardation
• Psychological instability
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indirect calorimetry using a ventilated hood system
(Omnical, Maastricht, the Netherlands). Details about
the techniques used can be found in the original study
by Vijgen et al. [17].
E.B. had full access to all data and takes responsibility
for data integrity and analysis.
Laboratory tests
On the days of either scan, fasting blood (EDTA plasma
and serum) was drawn right before the measurements
were done. On the day of the VNS-off scan, blood sam-
ples were taken after VNS was switched off, right before
injection of the tracer. Glucose was measured using a
hexokinase-based assay (Cobas 6000, Roche Diagnostics,
Mannheim, Germany) with a reference range of 3.1–7.8
mmol/L. Insulin was measured with Immulite XPi, Sie-
mens Healthcare, Erlangen, Germany). Initial results
were in mU/L and were converted to SI units with a fac-
tor of 6.00 (1 mU/L = 6.00 pmol/L) [18] with a reference
range between 12 and 150 pmol/L. C-reactive protein
(CRP) was measured using a turbidimetric assay (Cobas
8000) with a reference range of < 10 mg/L and a detec-
tion limit of > 1 mg/L.
PET protocol
A mean standard activity of 75 MBq 18F-FDG was
injected 1 h before scanning on a Gemini TF PET/CT
system (Philips Healthcare, Best, The Netherlands). For
attenuation correction and anatomical co-localization of
the PET signal, a low-dose native whole-body CT proto-
col (120 kVp, 30 mAs) was used. All scans were per-
formed after an overnight fast and confirmation of
appropriate glucose levels (< 7 mmol/L).
Image analysis
Analyses of the PET data were carried out using a com-
mercially available, dedicated workstation (Extended
Brilliance Workspace V4.5.3.40140; Philips Healthcare,
Best, The Netherlands). Circular regions of interest
(ROIs) were placed to delineate the outer contour of the
vessel wall of the common carotid artery and the aorta
(ascending aorta, aortic arch, thoracic descending aorta
(until the diaphragm) and abdominal aorta (until the
iliac bifurcation or as low as sufficiently imaged)). Since
all participants had a VNS implanted close to the left ca-
rotid sinus, only the right carotid artery was included in
the analysis in order to exclude local effects of the device
on 18F-FDG uptake in the left carotid artery. Standard
circular ROIs (diameter 20 mm) were placed on the cen-
ter of each thoracic and lumbar vertebra to measure
bone marrow (BM) activity. For the spleen, standard cir-
cular ROIs (diameter 20 mm) were placed centrally in
the spleen on each transversal plane. Visceral adipose
tissue (VAT) was measured with three circular 10 mm
ROIs placed in intra-peritoneal fat at the level of the
umbilicus. ROIs of the same size were placed in the nu-
chal subcutaneous adipose tissue (SAT) and in SAT at
the level of the xiphoid. The 18F-FDG activity within
each ROI was measured as the mean and maximum
standardized uptake value (SUVmean and SUVmax, re-
spectively). SUV represents activity concentration per
ROI normalized for the administered activity, corrected
for decay (dependent on injected activity and time) and
body weight of the subject. The SUVmean and SUVmax of
all ROIs were normalized for blood pool activity by
Table 2 Stimulation parameters
Subject Output current (mA) Frequency (Hz) Pulse width (μs) On-period (s) Off-period (s)
01 2.25 30 250 30 300
02 0.75 30 250 30 300
03* 1.5 30 250 7 20
04 0.75 30 250 30 300
06 1.25 30 500 30 300
10 2 30 250 30 300
11 1 30 250 30 300
12 1.75 30 250 7 18
13 2.25 30 250 30 300
14 2 30 250 30 300
In subject 03 (*), the VNS-off scan could not be reconstructed
Table 3 Subject characteristics (n = 10)
Age (years) 45 (33–52)
Sex (number of males) 4
Weight (kg) 67.4 (58.1–75.8)
BMI (kg/m2) 24.4 (22.6–26.2)
Time since implantation of VNS (months) 56 (46–66)
Time between experiments (days) 14 (14–49)
Median values are given with the IQR between brackets. Abbreviations: BMI
body mass index
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calculating target-to-background ratios (TBRs). To
achieve this, arterial SUVs were divided by the averaged
SUVmean (meanSUVmean) of at least three standard circu-
lar ROIs (diameter 4 mm) placed in the lumen of a ref-
erence vein. In the case of the carotid artery and nuchal
SAT TBRs, the jugular vein (JV) was used as the refer-
ence vein. For all other TBRs, the meanSUVmean of the
vena cava superior (VCS) was used to calculate the TBR.
Blood pool normalization of the SUVmean and SUVmax
resulted in the corresponding TBRmean and TBRmax.
Average TBRs were calculated per vascular territory.
ROIs were excluded from further analysis in case spill-in
of activity from adjacent structures was suspected or ar-
tifacts prevented the drawing of accurate ROIs.
Statistical analysis
Because of the small sample size, continuous data are
presented with their median and interquartile range
(Q1–Q3) and compared using the non-parametric Wil-
coxon signed rank test. Correlation was tested using the
Spearman correlation coefficient. Statistical significance
was defined at the 95% confidence level (p < 0.05). All
statistical analyses were performed with IBM SPSS Sta-
tistics for Mac OS X, version 24 (2015).
Results
Changes in energy expenditure and laboratory tests
When VNS was switched off, energy expenditure (EE)
decreased in nine out of ten patients (p = 0.047). In
addition, glucose levels tended to be higher after VNS
was switched off (4.8 mmol/L (4.7–5.3) vs. 4.6 mmol/L
(4.5–5.2); Fig. 1a), although this was not statistically sig-
nificant (p = 0.053). However, insulin levels increased
significantly in the VNS-off state (55.0 pmol/L (45.9–
96.8) vs. 48.1 pmol/L (36.9–61.8); p = 0.047; Fig. 1b).
CRP-levels did not significantly differ between scans (1.0
mg/L (0.8–2.0) during VNS-off vs. 1.2 mg/L (1.0–2.7)
during VNS-on; p = 0.445). Details can be found in
Table 4. Also see Additional file 1: Figure S1 for individ-
ual CRP levels.
Administered 18F-FDG activity did not differ between
scans (see Table 4). 18F-FDG blood pool activity in-
creased when VNS was turned off (SUVmean 1.2 (0.8–
1.3) vs. 0.9 (0.7–1.1), p = 0.066 for the jugular vein (Fig.
1c) and 1.3 (1.1–1.4) vs. 1.0 (0.8–1.1), p = 0.011 for the
Fig. 1 Change in glucose, insulin and venous 18F-FDG levels after VNS discontinuation. The change in glucose levels (a), insulin levels (b), and
average SUVmean values for the jugular veins (c) and vena cava superior (d) are shown per subject (n = 10 for a and b and n = 9 for c and d,
respectively). Generally, these measurements increased in most patients when VNS was switched off (VNS-OFF) in comparison to functional VNS
(VNS-ON). The dotted lines represent subject 03 and 12 in (a, b), whose stimulation parameters differed from those of the other subjects. Of these
two subjects, subject 12 shows the steepest increase in glucose and insulin levels. In (c, d), the dotted line represents values of subject 12
because the VNS-OFF scan of subject 03 could not be used for analysis. The dashed line represents subject 14, who was the only subject with
multiple cardiovascular risk factors
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VCS (Fig. 1d); see also Table 4). Blood pool activity did
not correlate to glucose or insulin levels when data of
both timepoints were combined. Only the off-scan insu-
lin levels correlated to the corresponding meanSUVmean
of the VCS (Spearman ρ = 0.745; p = 0.021). Further-
more, the blood pool activity, glucose, or insulin levels
did not correlate to EE, nor did the difference in blood
pool activity correlate to the difference in EE.
PET/CT image quality
In one of the VNS-on scans, ROIs could not be placed ac-
curately around the lumen of the abdominal aorta as well
as in the spleen and xiphoid SAT, due to movement of the
participant between the PET and CT scan, which resulted
in a disturbed attenuation and scatter correction. In an-
other VNS-on scan, VAT could not be analyzed due to a
truncation artifact because of high activity outside the field
of view of the accompanying low-dose CT reconstruction.
In one scan of one participant, the right carotid artery
could not be properly delineated and in another partici-
pant, spill-in of intestinal activity was suspected in the
VAT ROIs. Additionally, in the case of three lean patients,
the amount of adipose tissue was insufficient to ensure ad-
equate ROI placement in one or more of the adipose tis-
sue compartments. In total, the analysis was based on the
following number of participants; carotid artery n = 8; ab-
dominal aorta n = 8; spleen n = 8; nuchal SAT n = 7; xiph-
oid SAT n = 5; VAT n = 6. All other PET/CT analyses
were based on nine participants.
Effect of VNS on 18F-FDG activity in the arterial wall,
hematopoietic organs, and adipose tissue
Arterial SUVs tended to be higher after VNS was turned
off. However, this difference was only significant in the
aortic arch (p = 0.012) and the thoracic aorta (p =
0.038). In contrast, arterial TBRs tended to be non-
significantly lower after VNS was switched off than when
VNS was still turned on. For average arterial SUV and
TBR values per subject, see Additional file 2: Figure S2.
In line with the findings in the arterial territories,
SUVs tended to be higher in the spleen, BM, and SAT
after VNS was turned off, albeit not statistically signifi-
cant. Only in VAT, a slight though non-significant de-
crease in SUVs could be observed after VNS was turned
off. Furthermore, TBRs of the spleen, BM, SAT, and
VAT tended to increase after VNS was turned off com-
pared to the on-mode values. None of these differences
reached statistical significance. For details, see Table 5.
Correlations between TBRmax and laboratory tests
There were no statistically significant correlations be-
tween TBRmax values of the vessels or hematopoietic or-
gans, and CRP, glucose, or insulin levels. Only the off-
scan insulin levels correlated to the corresponding
TBRmax of xyfoid SAT (spearman ρ = − 0.829; p =
0.042).
Discussion
In this exploratory analysis, we aimed to investigate a
difference in arterial wall 18F-FDG uptake as a result of a
change in inflammatory status when chronic VNS was
discontinued. Switching off VNS only changed the SUV-
max significantly in some arterial territories. There was
no significant change in arterial TBRmax. However, even
though VNS was only discontinued for 3.5 h, insulin
levels and 18F-FDG blood pool activity did increase. The
latter resulted in an unexpected non-significant decrease
in arterial TBRs. It appears that VNS alters 18F-FDG
(and thus probably also glucose) distribution throughout
the body.
Previous research has shown arterial wall 18F-FDG up-
take to correlate to both plaque macrophage content
and the risk of future cardiovascular events [19, 20].
TBR is an accepted and commonly used outcome meas-
ure to study arterial wall inflammation [16]. The rela-
tively small size of the arterial wall in comparison to the
spatial resolution of 18F-FDG PET/CT makes delineating
the vascular wall challenging and in the current method,
the lumen is therefore included in the ROI. TBR is the
accepted method to compensate for this. The interpret-
ation of this correction is of particular interest in this
study, since SUV and TBR outcomes seem to contradict
Table 4 Laboratory tests, energy expenditure, core temperature, 18F-FDG activity, and blood pool activity
VNS-on VNS-off p-value
CRP (mg/L) N = 10 1.2 (1.0-2.7) 1.0 (0.8–2.0) 0.445
Glucose (mmol/L) N = 10 4.6 (4.5–5.2) 4.8 (4.7–5.3) 0.053
Insulin (pmol/L) N = 10 48.1 (36.9–61.8) 55.0 (45.9–96.8) 0.047
Energy expenditure (J/s) N = 10 70.4 (61.1–75.8) 68.4 (59.7–74.3) 0.047
18F-FDG activity (MBq) N = 9 76 (74–82) 79 (73–81) 0.766
Blood pool activity meanSUVmean JV N = 9 0.9 (0.7–1.1) 1.2 (0.8–1.3) 0.066
meanSUVmean VCS N = 9 1.0 (0.8–1.1) 1.3 (1.1–1.4) 0.011
Median values are given with the IQR between brackets. P values in bold indicate statistically significant findings. Abbreviations: CRP C-reactive protein, SUV
standardized uptake value, JV jugular vein, SCVCS vena superior cava veinsuperior
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one another. When VNS was switched off, SUVs were
higher than during VNS-on, suggesting an increase in
arterial wall inflammation due to a decrease in the anti-
inflammatory effect of VNS. This is in line with our hy-
pothesis that VNS decreases arterial wall inflammation.
However, the effect of VNS on blood pool activity was
larger at this time point, which resulted in a non-
significant decrease in TBRs after VNS was switched off.
The contradictory findings of the TBRs with respect to
the SUVs and to our hypothesis, and the relatively lim-
ited intervention, led us to explore alternative hypoth-
eses to account for the changes in arterial wall 18F-FDG
uptake beyond an effect on local inflammation.
Although 18F-FDG has proven its relevance in ath-
erosclerotic inflammation imaging, it is not specific
for this disease. As a glucose analogue, 18F-FDG’s up-
take is influenced by the same factors influencing glu-
cose uptake—demand and supply—and by
competition with dietary glucose. First of all, glucose
demand is increased in active tissues. For instance, an
increased 18F-FDG uptake can be observed in tumors
and inflammatory processes. Secondly, glucose supply
is dependent on blood flow and distribution. Thirdly,
18F-FDG uptake in a specific tissue depends on its
competition with dietary glucose and with the de-
mand for glucose from other tissues. Because of this
competition, patients should be fasted and have blood
glucose levels lower than 7 mmol/L before an 18F-
FDG PET/CT [16]. While our investigation aimed to
image a change in inflammatory activity due to VNS
treatment, it is possible that VNS also affected 18F-
FDG distribution via blood flow and/or systemic glu-
cose metabolism.
Multiple mechanisms can be proposed to explain an
altered 18F-FDG distribution due to VNS. The VN in-
cludes multiple fiber types, both afferent and efferent,
projecting to and originating from various nuclei in the
brain to and from almost every visceral organ [1]. Most
efferent fibers are cholinergic parasympathetic fibers, but
the VN also interacts with the sympathetic nervous sys-
tem on multiple levels [2]. The VNS electrode is posi-
tioned in such a way that pulses are primarily directed
in the afferent direction. In addition, extrapolation from
animal studies shows that, most likely, commonly used
VNS output currents stimulate mainly somatic and vis-
ceral afferent A-fibers [1, 4]. Concurrently, “side-effects”
of VNS are also most likely to result from afferent rather
than efferent stimulation.
The afferent VN is suggested to activate the sympa-
thetic nervous system in order to control inflammation
[7, 21], cardiac output, and blood pressure [22]. Stimula-
tion of the sympathetic nervous system could cause
blood flow to be altered due to peripheral, renal, and in-
testinal vasoconstriction [23]. If this is indeed the case,
one might expect an increase in blood pressure under
VNS stimulation. However, several studies in rats appear
to show no increase or even a decrease in blood pressure
by VNS [24–28]. In VNS trials in humans, heart rate
tends to be the main measure for cardiovascular safety
while possible effects on blood pressure are less well
studied [29]. Short-term (120 s) transcutaneous VNS did
not show an effect on blood pressure in healthy volun-
teers [30], nor did VNS in epilepsy patients at 16 weeks
after implantation [31]. Studies in epilepsy patients,
which had VNS treatment for a longer period, did not
show a difference in blood pressure between the on- and
off-period of VNS stimulation [29, 32]. In addition, des-
pite an increase in sympathetic responsiveness of blood
pressure, one study showed long-term VNS to result in
a decrease in blood pressure compared to baseline [32].
We therefore do not suspect altered blood flow to be the
main cause for the observed effect on 18F-FDG uptake in
the arterial wall and blood pool.
An alternative explanation for the observed 18F-FDG
distribution due to a sympathetic effect of VNS is the
Table 5 Maximum standardized uptake values (SUVmax) and
target-to-background ratios (TBRmax)
VNS-on VNS-off p value
Right carotid arterya SUVmax 1.3 (0.9–1.6) 1.5 (1.2–1.8) 0.093
TBRmax 1.5 (1.2–1.7) 1.2 (1.2–1.7) 0.484
Ascending aorta SUVmax 1.8 (1.3–2.0) 1.9 (1.7–2.4) 0.066
TBRmax 1.8 (1.6–2.0) 1.6 (1.5–1.7) 0.139
Aortic arch SUVmax 1.7 (1.2–2.1) 1.9 (1.5–2.4) 0.012
TBRmax 1.6 (1.5–2.1) 1.5 (1.4–1.8) 0.086
Thoracic aorta SUVmax 1.7 (1.2–2.1) 1.9 (1.6–2.4) 0.038
TBRmax 1.7 (1.5-2.1) 1.5 (1.4-1.7) 0.139
Abdominal aortaa SUVmax 1.7 (1.1-1.9) 1.7 (1.5-2.0) 0.401
TBRmax 1.6 (1.5–1.9) 1.4 (1.4–1.5) 0.093
All vessels SUVmax 1.7 (1.2–2.0) 1.8 (1.5–2.2) 0.051
TBRmax 1.7 (1.5–1.9) 1.5 (1.4–1.6) 0.086
Spleena SUVmax 1.6 (1.1–2.0) 1.8 (1.7–2.1) 0.069
TBRmax 1.7 (1.4–2.0) 1.5 (1.4–1.6) 0.327
Bone marrow SUVmax 2.4 (1.4–2.6) 2.3 (2.0–2.6) 0.594
TBRmax 2.1 (1.7–2.5) 1.8 (1.7–1.9) 0.110
Nuchal SATb SUVmax 0.4 (0.3–0.5) 0.5 (0.5–0.6) 0.310
TBRmax 0.4 (0.4–0.6) 0.4 (0.4–0.5) 0.499
Xiphoid SATc SUVmax 0.5 (0.4–0.8) 0.6 (0.5–0.9) 0.273
TBRmax 0.6 (0.4–0.8) 0.4 (0.3–0.6) 0.225
VATd SUVmax 0.7 (0.5–0.8) 0.6 (0.5–0.7) 0.462
TBRmax 0.7 (0.5–0.8) 0.4 (0.3–0.6) 0.173
When not stated otherwise, median values for the nine patients are given with
the IQR between brackets. an = 8 participants, bn = 7 participants, cn = 5
participants, dn = 6 participants. P values in bold indicate statistically
significant findings
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increase of insulin-independent glucose uptake in per-
ipheral tissues, mainly the skeletal muscles [33–35]. This
could explain the lower blood pool activity under VNS,
because of an increased uptake of 18F-FDG in the mus-
cles, which were outside the field of view for the most
part.
The VN also influences glucose metabolism through
systemic glucose storage and release, and through gluca-
gon and insulin levels. In the current study, both glucose
and insulin levels tended to be higher when VNS was
switched off than during VNS. This seems to be in
agreement with findings of simultaneous afferent and ef-
ferent stimulation of the VNS in rats. Afferent VNS
(both with and without concurrent efferent stimulation)
for a time period of 120 min resulted in a strong and
sustained increase in glucose levels, probably due to an
increased glucose release from the liver combined with
suppressed insulin secretion [36, 37]. Pure efferent VNS
mainly resulted in increased insulin levels [36]. An ex-
clusive increase in glucose levels could explain a lower
uptake of 18F-FDG in the target tissues due to an en-
hanced competition with glucose. In theory, however,
this would also increase the 18F-FDG blood pool activity.
In addition, previous research has shown 18F-FDG com-
petition with dietary glucose to only be relevant when
glucose levels exceed 7 mmol/L [16]. A sole increase of
insulin would increase general glucose- and thus 18F-
FDG uptake and would result in a decrease of the blood
pool activity of the tracer. Furthermore, since insulin in-
creases glucose (and thus 18F-FDG) uptake in multiple
tissues, an increase in insulin levels could also result in
lower uptake in a specific tissue, due to an increased
competition with other tissues. Excluding an effect of
insulin-independent peripheral uptake, a proportional
increase of insulin and glucose would cause the net re-
sult of 18F-FDG uptake to remain unchanged. It appears
therefore that our results are best explained by a com-
bination of afferent and efferent VN stimulation in
which increased insulin levels, and possibly insulin-
independent increased peripheral uptake, probably play
a more significant role than the increased glucose levels.
It is important to realize that both the anatomy of the
VN and VNS settings used in animal models differ from
the human situation. In the abovementioned studies, an-
imals were treated with continuous VNS, whereas in
humans, stimulation is non-continuous. Indeed, a recent
retrospective study showed an effect on blood glucose
levels of chronic VNS to depend on stimulation parame-
ters [38]. A long stimulation ON-period and a short
stimulation OFF-period were associated with higher glu-
cose levels on follow-up in epilepsy patients treated with
VNS. The most commonly used stimulation parameters
of our subjects (30 s ON, 300 s OFF) fall between the esti-
mated “neutral effect parameters” of the abovementioned
study and the stimulation parameters of the two subjects
with divergent parameters (subject 03 and 12) fall within
the “glucose lowering parameters” [38]. Although, subject
12 shows a relatively steep increase in glucose and insulin
levels after VNS is switched off, there is no clear trend
among the other subjects, and a larger study would be ne-
cessary to further investigate this hypothesis.
Although, we were unable to show an anti-
inflammatory effect of VNS on atherosclerosis, probably
due to the abovementioned effects on glucose metabol-
ism, it should also be taken into account that our popu-
lation of refractory epilepsy patients was relatively young
and only one participant (subject 14) had known classic
cardiovascular risk factors. Remarkably, this middle-aged
male subject, who was overweight and had both hyper-
tension and hypercholesterolemia, did show an increase
in arterial TBRs after VNS was switched off in contrast
to most participants (Additional file 2: Figure S2). Of
course, no conclusions can be drawn from this, since it
concerns a single patient, but it does strengthen our
conviction that VNS might indeed offer a therapeutic
option for atherosclerosis and other chronic inflamma-
tory diseases.
Strengths and limitations
A major strength of this study is that all patients served
as their own control. Since the same patients, the same
scan protocol, the same timing, and the same activity of
18F-FDG were used for both the VNS-on and VNS-off
scans.
Important drawbacks of this study are the small sam-
ple size and the short duration that VNS was turned off.
It was considered unethical to turn the VNS off for a
longer time period. A longer VNS-off period might have
resulted in larger differences in measurements in com-
parison to VNS-on, which would possibly have affected
the statistical significance of our findings. In addition,
we expect this to affect the concurring consequences of
VNS, such as changes in blood glucose levels, to a simi-
lar extent. In addition, we compared long-term stimula-
tion to short-term discontinuation, which is possibly
quite different from a VNS-naïve situation.
Another limitation is the lack of basic physical tests,
such as blood pressure and heart rate, which could
have supported our hypothesis of a sympathetic effect
of VNS.
It is also important to note that we did not perform
partial volume correction, since the used PET/CT sys-
tem did not feature a resolution recovery reconstruction
algorithm. This might have resulted in an underestima-
tion of the arterial wall uptake. However, since this is
true for both the VNS-on and the VNS-off scans, we ex-
pect that this did not significantly affect our results.
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In conclusion, short-term discontinuation of VNS al-
tered SUVmax for
18F-FDG in some arterial territories,
but not TBRmax. However, this intervention affected the
venous blood pool activity and insulin levels. It seems
therefore that VNS might have an effect on glucose me-
tabolism, possibly as a result of sympathetic activation.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13550-019-0567-9.
Additional file 1: Figure S1. Change in C-reactive protein levels after
VNS-discontinuation. Depicted are the C-reactive protein (CRP) levels for
individual subjects (n=10). The dotted lines represent subject number 03
and 12, whose stimulation parameters differed from the other subjects.
Subject 12 had the highest CRP value at the VNS-ON scan. The dashed
line represents subject number 14, who was the only subject with cardio-
vascular risk factors. In contrast to most other subjects, CRP was higher in
this subject after VNS was switched off than during the VNS-ON scan.
Additional file 2: Figure S2. Changes in average SUVmean, SUVmax,
TBRmean and TBRmax for all measured arterial territories after VNS-
discontinuation. Depicted are the average SUVmean, SUVmax, TBRmean and
TBRmax for all measured arterial territories combined for each individual
subject (n=9). These average values are based on those of the right ca-
rotid artery and of four areas in the aorta in n=7. In one subject the
values of both time points are based on the four arterial territories ex-
cluding the abdominal aorta, because of a disturbed scatter and attenu-
ation correction of the VNS-OFF scan. In another subject, the carotid
artery is not included in the average values, because it could not be suffi-
ciently delineated. The dotted line represents subject number 03, whose
stimulation parameters differed from the other subjects. The dashed line
represents subject number 14, who was the only subject with cardiovas-
cular risk factors. In contrast to most other subjects, TBRs were higher in
this subject after VNS was switched off.
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